Anatomic site variability in rat skeletal uptake and desorption of fluorescently labeled bisphosphonate

Oral Diseases

Volumn 17, Issue 4, 2011, Pages 427-432

  Wen, D ^a   Qing, L ^a,b   Harrison, G ^a   Golub, E ^a   Akintoye, S O ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Bisphosphonate; Bone; Fluorescent labeling; Jaw; Osteonecrosis

Indexed keywords

EDETIC ACID; FLUORESCENT DYE; HYDROXYAPATITE; PAMIDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DESORPTION; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; FLUOROMETRY; JAW OSTEONECROSIS; MANDIBLE; NONHUMAN; PRIORITY JOURNAL; RAT; SKELETON;

ANIMALS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CHELATING AGENTS; DECALCIFICATION TECHNIQUE; DIPHOSPHONATES; DURAPATITE; EDETIC ACID; FEMALE; FEMUR; FIBULA; FLUORESCENT DYES; FLUOROMETRY; HUMERUS; INJECTIONS, INTRAVENOUS; MANDIBLE; MODELS, ANIMAL; RADIUS; RATS; RATS, NUDE; SPECTROPHOTOMETRY, ATOMIC; TIBIA; TISSUE DISTRIBUTION; ULNA;

EID: 79953741598     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2010.01772.x     Document Type: Article

References (28)

1. Allen MR (2009a). Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench. Cells Tissues Organs 189: 289-294.
2. Allen MR (2009b). Does rat + bisphosphonate + exposed bone = an animal model of ONJ? IBMS BoneKEy 2009, June 1, doi:, International Bone and Mineral Society: Washington, DC, pp. 227-231.
3. Allen MR, Burr DB (2008). Mandible matrix necrosis in beagle dogs after 3years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 66: 987-994.
4. Bauss F, Lalla S, Endele R, Hothorn LA (2002). Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J Rheumatol 29: 2200-2208.
5. Bauss F, Pfister T, Papapoulos S (2008). Ibandronate uptake in the jaw is similar to long bones and vertebrae in the rat. J Bone Miner Metab 26: 406-408.
6. Ezra A, Golomb G (2000). Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev 42: 175-195.
7. Fleisch H (1998). Bisphosphonates: mechanisms of action. Endocr Rev 19: 80-100.
8. Fleisch H (2000). Bisphosphonates in bone disease: from the laboratory to the patient. Academic Press: San Diego.
9. Fuchs RK, Allen MR, Condon KW et al (2008). Calculating clinically relevant drug doses to use in animal studies. Osteoporos Int 19: 1815-1817.
10. Hansen T, Kunkel M, Weber A, James Kirkpatrick C (2006). Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35: 155-160.
11. Huja SS, Fernandez SA, Hill KJ, Li Y (2006). Remodeling dynamics in the alveolar process in skeletally mature dogs. Anat Rec A Discov Mol Cell Evol Biol 288: 1243-1249.
12. Idris AI, Rojas J, Greig IR, Van't Hof RJ, Ralston SH (2008). Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 82: 191-201.
13. Jung A, Bisaz S, Bartholdi P, Fleisch H (1973). Influence of pyrophosphate on the exchange of calcium and phosphate ions on hydroxyapatite. Calcif Tissue Res 13: 27-40.
14. Lin JH, Chen IW, Duggan DE (1992). Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Dispos 20: 473-478.
15. Marx RE, Sawatari Y, Fortin M, Broumand V (2005). Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63: 1567-1575.
16. Migliorati CA, Schubert MM, Peterson DE, Seneda LM (2005). Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104: 83-93.
17. Migliorati CA, Siegel MA, Elting LS (2006). Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 7: 508-514.
18. Reid IR, Bolland MJ, Grey AB (2007). Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 41: 318-320.
19. Rodan GA, Fleisch HA (1996). Bisphosphonates: mechanisms of action. J Clin Invest 97: 2692-2696.
20. Rogers MJ (2003). New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9: 2643-2658.
21. Ruggiero SL, Fantasia J, Carlson E (2006). Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102: 433-441.
22. Sarin J, DeRossi SS, Akintoye SO (2008). Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis 14: 277-285.
23. Sato M, Grasser W, Endo N et al (1991). Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88: 2095-2105.
24. Sonis ST, Watkins BA, Lyng GD, Lerman MA, Anderson KC (2009). Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol 45: 164-172.
25. Stefanik D, Sarin J, Vogell A, Levin L, Leboy PS, Akintoye SO (2006). Effects of pamidronate on oro-facial human bone marrow stromal cells. J Dent Res 85: 430.
26. Stefanik D, Sarin J, Lam T, Levin L, Leboy PS, Akintoye SO (2008). Disparate osteogenic response of mandible and iliac crest bone marrow stromal cells to pamidronate. Oral Dis 14: 465-471.
27. Woo SB, Hellstein JW, Kalmar JR (2006). Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144: 753-761.
28. Zaheer A, Lenkinski RE, Mahmood A, Jones AG, Cantley LC, Frangioni JV (2001). In vivo near-infrared fluorescence imaging of osteoblastic activity. Nat Biotechnol 19: 1148-1154.